

## CONTACTS & KEY INFORMATION

<b>Headquarters</b>	Skininvisible, Inc. 6320 S. Sandhill Rd., #10 Las Vegas, NV 89120
<b>Stock</b>	OTC Bulletin Board
<b>Symbol</b>	'SKVI'
<b>Website - Corp</b>	www.skininvisible.com
<b>- Product</b>	www.invisicare.com
<b>Out. Shares</b>	70,739,248
<b>Public Float</b>	55%
<b>Inside Owners</b>	45%
<b>Sector</b>	Topical drug delivery technology for pharmaceuticals and cosmetics

## MANAGEMENT TEAM

**Terry Howlett**  
President and Chief Executive Officer

**Dr. James A. Roszell**  
Vice President, Research and Development

**Teresa Petraia**  
Business Development

## SELECTED RECENT NEWS

**Breaking News: 01/30/2008: Skininvisible® Announces Licensing Agreement for Adapalene – The Company's First Acne Product Enter the \$2.8 Billion Worldwide Market** LAS VEGAS, Nevada. January 30, 2008 – Skininvisible, Inc. (OTCBB: SKVI / Website: [www.skininvisible.com](http://www.skininvisible.com)), a research and development company focused on formulating and enhancing patented dermatology products with their proprietary polymer delivery system Invisicare®, announced it has signed an exclusive licensing agreement with Panalab Internacional S.A. ("Panalab"). The Agreement is for the right to develop and commercialize Skininvisible's prescription anti-acne products formulated with adapalene and Invisicare® in Argentina, Brazil and Chile. Under the terms of the agreement Panalab, a multi-national dermatology company headquartered in Panama with subsidiaries and partners in most Latin American countries will be responsible for filing and obtaining marketing approval in the countries they have licensed. While all terms of the agreement were not disclosed, Skininvisible will receive a research and development fee plus milestone payments. In addition the Company will receive royalties based on revenues generated by the sale of the products. According to the agreement, Panalab will have the right to manufacture, distribute, market, sell and promote the adapalene formulations in the specified territory. "We are very pleased to sign this agreement with Panalab brought to us by Riley-Nacht, LLC, one of our pharmaceutical consulting firms representing our products and technology to international pharmaceutical and cosmeceutical companies," said Mr. Terry Howlett, President/CEO of Skininvisible. "The acne market is extremely large, with retinoids like adapalene making up the largest portion with over 60% market share. We are entering the acne market with adapalene as it is the market leader and we are confident that dermatology companies will be interested in obtaining the rights to our Invisicare® formulations incorporating adapalene, especially with our ability to seek patent protection for these products in the United States.

## HIGHLIGHTS...

► **SKINVISIBLE IS A DRUG-DELIVERY COMPANY THAT OUT-LICENSES ITS INVISICARE® FAMILY OF POLYMER DELIVERY VEHICLES** which, when topically applied, hold their active ingredients on the skin for up to four hours thereby affording the active agents an extended time- frame to perform their intended functions. The Company's superior polymer delivery platforms are designed to significantly enhance product performance for established brand manufacturers of prescription, as well as over-the-counter (OTC), dermatological, medical, cosmetic and skincare products.

► **TYPICALLY, SKINVISIBLE'S LICENSING AGREEMENTS INCLUDE EXCLUSIVITY FOR A SPECIFIED TOPICAL SKIN APPLICATION WITHIN A DEFINED TERRITORY.** Skininvisible licenses its patented technology to established developers and manufacturers of dermatological, medical, cosmetic and skincare products, thereby granting them the right to incorporate Invisicare® polymer delivery vehicles into identified product formulations. Under these agreements, Skininvisible receives a license fee upfront and ongoing royalty payments on formulated product sales.

► **THE NUCLEUS OF SKINVISIBLE'S INVISICARE® FAMILY OF POLYMER DELIVERY VEHICLES IS ITS FORMULA AND PROCESS FOR COMBINING HYDROPHILIC AND HYDROPHOBIC POLYMERS INTO STABLE COMPLEXES IN WATER EMULSIONS.** This allows formulated products using Invisicare® as their platform to remain on the skin for extended periods of time, resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. Skininvisible's process for combining water-soluble and insoluble polymers is specifically formulated to carry water-insoluble active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. Products utilizing Invisicare® have the proven ability to bond active ingredients to the skin for up to four or more hours. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing the skin and forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. The invisible polymer compositions wear off as part of the natural exfoliation process of the skin's outer layer of cells.

### PRODUCTS

Skininvisible has developed a patented technology and trade marked its associated family of polymer delivery vehicles under the name Invisicare®. The Invisicare® product family offers five distinctive polymer formulations that hold active ingredients onto the skin.

#### Licensed Technology / Invisicare® Polymer Delivery Vehicles

Skininvisible licenses its patented technology to established developers and manufacturers of dermatological, medical, cosmetic and skincare products, thereby granting them the right to incorporate Invisicare® polymer delivery vehicles into identified product formulations.

#### Pipeline of Products Available for Licensing

- Acne
- Atopic Dermatitis
- Antifungal
- Daily Moisturizers
- Hand Sanitizers
- Sun Care
- Sunless Tanning

with  
**INVISICARE®**  
Polymer™  
Delivery System

**SAFE4  
HOURS**  
ANTIMICROBIAL LOTION

**Stopain**

solerra™